Title : Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer.

Pub. Date : 2017 Jun 20

PMID : 28427213






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The impact of continued crizotinib therapy on the patients" PFS2 time was assessed after adjusting for potential confounding factors. Crizotinib GINS complex subunit 2 Homo sapiens
2 With continued crizotinib therapy after documentation of PD, the median PFS2 for all 33 patients was 16 weeks, and in those with CNS progression but systemic disease control it was 30 weeks. Crizotinib GINS complex subunit 2 Homo sapiens
3 Multivariable Cox regression analysis showed that the PFS1 with initial crizotinib treatment and local therapy were independent predictors of PFS2. Crizotinib GINS complex subunit 2 Homo sapiens